Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025

Page 11 of 14

4. Compass Therapeutics Inc (NASDAQ:CMPX)

Number of Hedge Fund Holders In Q3 2024: 13

Compass Therapeutics Inc (NASDAQ:CMPX) is a clinical-stage oncology-focused biopharma company.

The stock has risen significantly so far in 2025 due to its clinical progress. Phase 2/3 top-line data for biliary tract cancer (BTC) is expected in Q1 2025. Tovecimig (CTX-009) has the potential for accelerated approval.

Moreover, a Phase 2 trial in DLL4-positive colorectal cancer is planned for mid-2025. CTX-8371 also fully enrolled the third cohort for the Phase 1 dose-escalation study; preliminary data is expected in H2 2025.

There is also a new drug candidate called CTX-10726.

The consensus price target of $11.8 implies 281.26% upside.

CMPX stock is up 109.31% year-to-date.

Page 11 of 14